These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23213054)

  • 1. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
    Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
    Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
    Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
    PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and preclinical characterization of a humanized antibody targeting CXCL12.
    Zhong C; Wang J; Li B; Xiang H; Ultsch M; Coons M; Wong T; Chiang NY; Clark S; Clark R; Quintana L; Gribling P; Suto E; Barck K; Corpuz R; Yao J; Takkar R; Lee WP; Damico-Beyer LA; Carano RD; Adams C; Kelley RF; Wang W; Ferrara N
    Clin Cancer Res; 2013 Aug; 19(16):4433-45. PubMed ID: 23812669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.
    Bertolini F; Dell'Agnola C; Mancuso P; Rabascio C; Burlini A; Monestiroli S; Gobbi A; Pruneri G; Martinelli G
    Cancer Res; 2002 Jun; 62(11):3106-12. PubMed ID: 12036921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.
    Broussas M; Boute N; Akla B; Berger S; Beau-Larvor C; Champion T; Robert A; Beck A; Haeuw JF; Goetsch L; Bailly C; Dumontet C; Matthes T; Corvaia N; Klinguer-Hamour C
    Mol Cancer Ther; 2016 Aug; 15(8):1890-9. PubMed ID: 27297868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
    Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
    Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
    Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
    Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
    Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
    Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
    Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
    Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
    Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
    Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
    Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.
    Hu Y; Gale M; Shields J; Garron C; Swistak M; Nguyen TH; Jacques G; Fogle R; Siders W; Kaplan J
    Leuk Lymphoma; 2012 Jan; 53(1):130-8. PubMed ID: 21740294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.